注：# 通讯； *第一作者 

Schulze CJ*, Seamon KJ*, Zhao Y*, Yang YC, Cregg J, et al. Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS. Science 2023;381(6659):794-795.

Kim D*, Herdeis L*, Rudolph D*, Zhao Y, Böttcher J, Vides A, et al. Pan-KRAS inhibitor disables oncogenic signalling and tumour growth. Nature 2023, 1-7. 

Zhao Y*, Murciano-Goroff YR*,.…., Lipford JR#, Li BT.# and Lito P#. Diverse alterations associated with resistance to KRAS(G12C) inhibition. Nature 2021; 599:679–683.

Xue J*, Zhao Y*, Aronowitz J, Vides A, Qeriqi B, Kim DS, Stanchina E, Riely G, Mazutis L, Risso D and Lito P#. Rapid non-uniform adaptation to conformation-specific KRASG12C inhibition. Nature 2020;1-5. 

Li C, Vides A, Kim DS, Xue J, Zhao Y, Lito P#. KRAS oncoprotein inactivation through enhanced GTPase activity. Science 2021; 374 (6564):197-201.

Zhao Y, Xue J, Lito P#. Suppressing nucleotide exchange to inhibit KRAS-mutant tumors. Cancer Discovery 2021; 11:17-9. 

全部发表文章请见：

https://pubmed.ncbi.nlm.nih.gov/?term=%28%28Yulei+Zhao%5BAuthor%5D%29+AND+%28MSKCC%5BAffiliation%5D%29%29+OR+%28%28Yulei+Zhao%5BAuthor%5D%29AND+%28Queen%27s+University%5BAffiliation%5D%29%29+OR+%28%28Yulei+Zhao%5BAuthor%5D%29+AND+%28Fudan+University%5BAffiliation%5D%29%29&sort=date